Biocon has received an approval for merger of its subsidiary Clinigene International with Syngene International. The board of director at its meeting held on July 25, 2013 has taken the note of it.
Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.